Remote | Biotech Investment Analyst — $125–$185/hour

24-Mag•New York, NY

6d•$125 - $185•Remote

About The Position

We are sharing a specialised part-time consulting opportunity for experienced biotech investment professionals with deep expertise in evaluating pharmaceutical assets, clinical-stage drug-development programmes, company fundamentals, and investment opportunities within the US biotech and healthcare market. This role supports an expert evaluation initiative focused on commercial drugs and drug-development programmes. Selected professionals will develop and critique structured evaluation rubrics, assess individual drug assets and the companies behind them, and apply specialist investment judgement across a focused set of biotech companies.

Requirements

5+ years of experience evaluating biotech, pharmaceutical, or healthcare companies or assets
Professional experience as a biotech or healthcare investment analyst, ideally within a specialist investment fund
Strong familiarity with biotech and pharmaceutical drug-development programmes
Experience assessing drug assets from scientific, clinical, commercial, and investment perspectives
Strong understanding of clinical data, mechanisms of action, competitive landscapes, and biotech valuation drivers
Ability to evaluate both individual assets and the broader companies developing them
Experience developing, reviewing, or presenting investment theses
Strong analytical judgement and ability to identify unsupported or incomplete assumptions
US-based or possessing deep professional experience covering the US biotech and healthcare investment market
Availability for approximately 10–20 hours over an initial 1–2 week pilot
Work must be completed without using confidential or proprietary information belonging to any employer, client, fund, institution, or other third party

Responsibilities

Evaluate commercial and clinical-stage drug assets across different therapeutic areas
Assess mechanism of action, biological rationale, clinical data, development progress, and regulatory considerations
Analyse competitive positioning within relevant therapeutic and treatment landscapes
Identify key scientific, clinical, regulatory, and commercial value drivers
Flag unsupported assumptions, evidence gaps, or material risks within asset assessments
Conduct end-to-end assessments of biotech and pharmaceutical companies
Evaluate pipeline quality, company strategy, competitive differentiation, and major catalysts
Assess the relationship between individual drug assets and overall company valuation
Review investment-style theses for analytical strength, supporting evidence, and internal consistency
Identify weak, overly confident, or missing assumptions within investment conclusions
Apply consistent investment judgement across approximately 5–10 companies during the pilot
Interpret clinical trial results and assess the strength and relevance of available evidence
Evaluate potential differentiation against existing and emerging standards of care
Analyse addressable markets, competitive dynamics, development timelines, and commercial opportunity
Assess how clinical, regulatory, and market developments may affect asset and company value
Distinguish between well-supported conclusions and speculative investment assumptions
Create structured evaluation rubrics for biotech companies and drug-development programmes
Critique existing rubrics for completeness, realism, and investment relevance
Define criteria reflecting experienced biotech investment judgement
Identify missing considerations or weak assumptions in analytical frameworks
Provide clear written reasoning supporting evaluation decisions